

Prior Authorization Request Form for Obesity Treatment Agents

FAX this completed form to (844) 205-3386 OR Mail requests to: PA Department | 5 River Park Place East, Suite 210 | Fresno, CA 93720

☐New request ☐Renewal request	# of pages:	Prescriber name:			
Name of office contact:		Specialty:			
Contact's phone number:		NPI:	State license #:		
LTC facility contact/phone:		Street address:			
Beneficiary name:		City/state/zip:			
Beneficiary ID#:	DOB:	Phone:	Fax:		
CLINICAL INFORMATION					
Drug requested:					
Strength & package size/quantity/refills:					
Additional strengths / quantity for each / refills for each to allow for dose titration:					
Directions:					
Diagnosis (submit documentation):			Dx code (<u>required</u>):		
For a non-preferred Obesity Treatment Agent, does the beneficiary have a history of trial and failure of or a contraindication or an intolerance to the preferred Obesity Treatment Agents appropriate for the beneficiary's diagnosis or indication? Refer to https://papdl.com/preferred-drug-list for a list of preferred and non-preferred drugs in this class.			☐Yes ☐No Submit documentation.		
Does the beneficiary have any contraindications to the requested medication?			☐Yes ☐No Submit documentation.		
ATTESTATION from the prescriber: Was beneficiary recently counseled about lifestyle changes and behavior modifications such as a healthy diet and increased physical activity?			☐Yes ☐No		

Complete all sections that apply to the beneficiary and this request.

Check all that apply and <u>submit documentation</u> for each item.

		INITIAL requests			
1.	The beneficiary is 18 years of age or older:				
	Pre-treatment weight: P	re-treatment BMI:			
	☐ Has a BMI greater than or equal to 30 kg/m²				
	☐ Has a BMI greater than or equal 27 kg/m² and less	s than 30 kg/m ² and at least one of the following weight-related comorbidities:			
	dyslipidemia	obstructive sleep apnea			
	hypertension	☐prediabetes			
	metabolic syndrome	☐type 2 diabetes			
	☐ Is a candidate for treatment based on degree of adiposity, waist circumference, history of bariatric surgery, BMI exceptions for beneficiary's ethnicity, etc. and has at least one of the following weight-related comorbidities:				
	<u> </u>	<u> </u>			
	☐dyslipidemia ☐hypertension	obstructive sleep apneaprediabetes			
	metabolic syndrome	☐type 2 diabetes			
2.	The beneficiary is less than 18 years of age:				
	Pre-treatment BMI: Pre-treatment BMI z-score:				
	☐ Has a BMI in the 95th percentile or greater standardized for age and sex based on current CDC charts				
3.	Request is for Evekeo (amphetamine) ODT/tablet:				
	Was assessed for potential risk of misuse, abuse, and/or addiction based on family and social history				
	Was educated regarding the potential adverse effects of stimulants, including the risk of misuse, abuse, and addiction				
	Has a history of trial and failure of or a contraindication or an intolerance of all other Obesity Treatment Agents (preferred and				
	non-preferred)				
	 ☐ Has prescriber documentation explaining why Evekeo (amphetamine) is needed and a plan for tapering ☐ For a beneficiary with a history of substance dependency, abuse, or diversion: 				
	☐ Has results of a recent UDS for licit & illicit drugs with the potential for abuse (including specific testing for oxycodone,				
	fentanyl, and tramadol) that is consistent with prescribed controlled substances				
	RI	ENEWAL requests			
4	All requestor				
1.					
	☐ The dose of the requested medication is currently being titrated ☐ The beneficiary is experiencing clinical benefit with the requested medication				
2.	The beneficiary is 18 years of age or older:				
	Pre-treatment weight:	Current weight:			
3.	The beneficiary is less than 18 years of age:				
	Pre-treatment BMI:	Current BMI:			
	Pre-treatment BMI z-score:	Current BMI z-score:			
4.	Request is for Evekeo (amphetamine) ODT/tablet:				
		keo (amphetamine) is needed and a plan for tapering (submit documentation)			

For a beneficiary with a history of substance dependency, abuse, or diversion: Has results of a recent UDS for licit & illicit drugs with the potential for abuse (including fentanyl, and tramadol) that is consistent with prescribed controlled substances	g specific testing for oxycodone,			
ADDITIONAL RATIONALE FOR REQUEST / PERTINENT CLINICAL INFOR	RMATION			
PLEASE <u>FAX</u> COMPLETED FORM WITH <u>REQUIRED CLINICAL DOCUMENTATION</u> TO DHS – PHARMACY DIVISION				
Prescriber Signature:	Date:			

Confidentiality Notice: The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited. PA Department will respond via fax or phone within 24 hours.

Requests for prior authorization (PA) requests must include member name, ID#, and drug name. Please include lab reports with requests when appropriate (e.g., Culture and Sensitivity; Hemoglobin A1C; Serum Creatinine; CD4; Hematocrit; WBC, etc.)

Rev 01/2024 v1